Summary
The extracted claims contain multiple specific assertions about missed doses, symptom effects, relapse risk, pharmacokinetics, and dosing adjustments. The provided label excerpts do not contain supporting information for these claims, and the evaluation basis itself is not sufficient to confirm true label absence across the full prescribing information.
Category Scores
Accurate Statements
Unsupported Statements
Missing a weekly dose of Avonex (interferon beta-1a) can lead to decreased efficacy in managing multiple sclerosis (MS) symptoms.
No supporting label text was found in the provided excerpts.
The immediate side effects of missing an Avonex dose are generally mild.
No supporting label text was found in the provided excerpts.
Some people may experience fatigue upon missing an Avonex dose.
No supporting label text was found in the provided excerpts.
Some people may experience headache upon missing an Avonex dose.
No supporting label text was found in the provided excerpts.
Some people may experience joint pain upon missing an Avonex dose.
No supporting label text was found in the provided excerpts.
Immediate effects upon missing an Avonex dose usually resolve within a day or two.
No supporting label text was found in the provided excerpts.
Skipping Avonex doses can lead to a higher risk of MS activity and relapses.
No supporting label text was found in the provided excerpts.
Avonex works best when taken consistently.
No supporting label text was found in the provided excerpts.
Taking Avonex consistently maintains a stable blood concentration of the medication.
No supporting label text was found in the provided excerpts.
Patients who missed more than 4 doses of Avonex within a 12-week period had a higher risk for MS relapses.
No supporting label text was found in the provided excerpts (this includes a specific threshold and timeframe).
Adjusting the dosing schedule for Avonex can maintain treatment efficacy.
No supporting label text was found in the provided excerpts.
Contradictions
Important Omissions
Label-supported missed-dose management guidance (e.g., what to do after a missed weekly dose), if any, is not reflected in the extracted claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Several claims make specific efficacy/safety/PK and timing-based statements about missed dosing and relapse risk without support in the provided prescribing-information excerpts. If used clinically, these could misinform patient expectations and decision-making.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple specific missed-dose efficacy, symptom, relapse, PK, and dosing-adjustment claims are not supported by the provided label excerpts.
Suggested Improvement
Restrict statements to text explicitly present in the prescribing information provided; remove missed-dose/relapse/PK/time-to-resolution and dosing-adjustment threshold claims unless supported by label language in the included sections.